EVALUATION OF POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN ISLATRAVIR AND LENACAPAVIR
Co-administration of islatravir (ISL), a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir (LEN), a capsid inhibitor, has the potential to offer a safe and efficacious oral once weekly regimen for the treatment of HIV-1 infection. ISL is not a substrate of cytochrome P450 (CYP) enzymes and is primarily metabolized via adenosine deaminase, with significant elimination…